ICM
SPRO icon

Ionic Capital Management’s Spero Therapeutics SPRO Stock Holding History

Ionic Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Sell
102,698
-93,241
-48% -$244K 0.03% 91
2026
Q1 		$458K Hold
195,939
– – 0.03% 89
2025
Q4 		$457K Sell
195,939
-12,786
-6% -$29.7K 0.06% 82
2025
Q3 		$392K Buy
208,725
+58,725
+39% +$129K 0.04% 97
2025
Q2 		$435K Buy
+150,000
New +$216K 0.12% 87

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ionic Capital Management's SPRO Position: Q2 2026 in Review

Ionic Capital Management reduced its Spero Therapeutics (SPRO) stake by 48% in Q2 2026, selling an estimated $244K and leaving 102,698 shares worth $227K. The position accounts for 0.03% of the portfolio, ranked #91.

Ionic Capital Management first reported a position in SPRO in Q2 2025 and has held it in 5 quarters since. The position peaked at $458K in Q1 2026. 59 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Ionic Capital Management held 102,698 shares of Spero Therapeutics worth $227K as of Q2 2026.
  • Ionic Capital Management sold 93,241 Spero Therapeutics shares in Q2 2026, an estimated $244K.
  • Spero Therapeutics made up 0.03% of Ionic Capital Management's portfolio in Q2 2026, its #91 holding.
  • Ionic Capital Management first reported a position in Spero Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Ionic Capital Management's Spero Therapeutics position peaked at $458K in Q1 2026.
  • 59 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Ionic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.